ISTM

Dr Murray Brunt is active on 8 national/international breast cancer trial management groups. For the majority of trials in which he as been involved, Dr Brunt has been the principal investigator for North Staffordshire and  involved in all local aspects from the initiation, set up, recruitment through to follow up until trial closure.

Dr Brunt initiated the first weekly clinical trial follow up clinic in the Guy Hilton Research Centre, which has been running since 2007.  He been a major collaborator on a total of 38 national or international studies and is the first chair of the Greater Midlands Cancer Network Research and Development Steering Committee when it was formed in 2007.

ISTM Research themes:
1. Clinical & Diagnostic Science
2. Bioengineering & Therapeutics

Dr Brunt’s research is in breast cancer, haematological malignancies (predominantly lymphomas), and skin cancer. It is conducted primarily through breast cancer clinical trials, on three levels:
- trial development, management, and  publication of results.
- a principal investigator and recruiter to trials
- the practical application of clinical trials and patient interaction.

The areas of breast cancer trials in which Dr Brunt is involved directly relate to his practice as a clinical oncologist:
- radiotherapy,
- chemotherapy,
- hormone therapy,
- targeted biological therapy

Recent publications:

The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial
The Lancet Oncology, Volume 9, Issue 4, April 2008, Pages 331-341

The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial
The Lancet, Volume 371, Issue 9618, 29 March 2008-4 April 2008, Pages 1098-1107

The Adjuvant Breast Cancer Trials Collaborative Group. Polychemotherapy for Early Breast Cancer: Results From the International Adjuvant Breast Cancer Chemotherapy Randomized Trial. J Natl Cancer Inst 2007; 99: 506-515

The Adjuvant Breast Cancer Trials Collaborative Group. Ovarian Ablation or Suppression in Premenopausal Early Breast Cancer: Results From the International Adjuvant Breast Cancer Ovarian Ablation or Suppression Randomized Trial. J Natl Cancer Inst 2007; 99: 516-525

C J Poole, H M Earl, L Hiller, J A Dunn, S Bathers, R J Grieve, A M Brunt et al. Epirubicin and Cyclophosphamide, Methotrexate, Fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 2006;355:1851-1862.

A M Brunt. What's new in radiotherapy for breast cancer? Trends in Urology Gynaecology and Sexual Health 2005;10:11-14.

A M Brunt. Cancer management: how is England faring? Geriatric Medicine 2005;5:43-8.

Deakin M, Brunt AM, Stephens M and Chasty RC. Lymphomas. Chapter in Upper Gastrointestinal Surgery, Eds Fielding JW & Hallisey M. 2005;231-240. Publisher Springer ISBN 1852336072.

Featherstone CJ, Harnett AN, Brunt AM and Johnson L. Methods of ovarian suppression used in the UK. The Breast. 2002;11:23-29.

Stringer NJ, Fitzpatrick RW and Brunt AM. Economic evaluation of a standard dosage system for an outpatient breast cancer chemotherapy regimen. Int J Pharm Pract. 2001;9:185-189.

Hartley A, Spooner D and Brunt AM. Management of malignant phaeochromocytoma: a retrospective review of the use of MIBG and chemotherapy in the West Midlands. Clinical Oncology. 2001;13:361-366.

Featherstone C, Harnett AN and Brunt AM. Ultrasound localisation of the ovaries for radiation-induced ovarian ablation. Clinical Oncology. 1999;11:393-397.

Brunt AM. The UKCCCR Adjuvant Breast Trial. Clinical Oncology. 1994;6:209-210 (Editorial)

Brunt AM and Scoble JE. Para-aortic nodal irradiation for early stage testicular seminoma. Clinical Oncology. 1992;4:165-170.

Sule-Suso J and Brunt AM. Small cell carcinoma of the prostate. British Journal of Radiology. 1992;65:726-728.

Sul;e-Suso J, Brunt AM, Lindup R and Scoble JE. Hyperfractionated accelerated radiotherapy for carcinoma of the oesophagus. Clinical Oncology. 1991;3:209-213.

Retsas S, Bafaloukos D and Brunt AM. Alpha-interferons; impact on survival of patients with renal cell carcinoma. Clinical Oncology. 1991;3:273-277.

Charlton CDA, Boote DJ, Brunt AM and Phillips RH. Place of radiotherapy and chemotherapy in the management of salivary gland tumours. Chapter in Head and Neck Oncology for the General Surgeon, Eds Preece PE, Rosin RD and Moran AGD. 1991; 193-233:W B Saunders Company.

Barr LC, Brunt AM, Phillips RH & Ellis H. Salvage mastectomy after failed breast conserving therapy for carcinoma of the breast. Annals of the Royal College of Surgeons of England 1991;73:126-129.

Brunt AM and Phillips RH. Strontium-90 for conjunctival AIDS-related Kaposi’s Sarcoma: The first case report. Clinical Oncology 1990;2:118-119.

Brunt AM, Goodman AG, Phillips RH, Youle MS and Gazzard BG. The safety of intravenous chemotherapy and zidovudine when treating Epidemic Kaposi's Sarcoma. AIDS. 1989;3:457-460.

Barr LC, Brunt AM, Goodman AG, Phillips RH and Ellis H. Uncontrolled local recurrence following treatment of breast cancer with breast conservation. Cancer. 1989;64:1203-1207.

Barr LC, Brunt AM et al. The primary management of breast cancer: Is breast conservation feasible for all patients? Annals of the Royal College of Surgeons of England 1989;71:390-393.

Professional Memberships:
- Medical Defence Union
- Royal College of Radiologists
- Royal College of Physicians, London
- British Oncology Association
- Radiotherapists Visiting Society
- Hospital Consultant & Specialists Association
- North Staffordshire Medical Institute

Committee Memberships:
- National deputy lead for the Breast Site Orientated electronic Network (SOeN): 2006-present.
- Member of National Collaborating Centre for Cancer (NCCC) advanced breast cancer guideline development group: 2006-9 (the lifetime of the project).
- Member of West Midlands Cancer Intelligence Unit steering committee: 2005-present.
- Member of Regional peer review team from 1997, clinical team leader from 2005-present.
Chair of R & D steering committee: 2007 to present.
- Deputy Lead of NCRN R & D for North West Midlands Cancer Network 2004-6 (until networks amalgamated).